Cargando…

The HSP90 Inhibitor Ganetespib Alleviates Disease Progression and Augments Intermittent Cyclophosphamide Therapy in the MRL/lpr Mouse Model of Systemic Lupus Erythematosus

Systemic lupus erythematosus (SLE) is a complex, systemic autoimmune disease with a diverse range of immunological and clinical manifestations. The introduction of broad spectrum immunosuppressive therapies and better management of acute disease exacerbations have improved outcomes for lupus patient...

Descripción completa

Detalles Bibliográficos
Autores principales:	Liu, Yuan, Ye, Josephine, Shin Ogawa, Luisa, Inoue, Takayo, Huang, Qin, Chu, John, Bates, Richard C., Ying, Weiwen, Sonderfan, Andrew J., Rao, Patricia E., Zhou, Dan
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2015
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4431681/ https://www.ncbi.nlm.nih.gov/pubmed/25974040 http://dx.doi.org/10.1371/journal.pone.0127361

Ejemplares similares

Phase I Evaluation of STA-1474, a Prodrug of the Novel HSP90 Inhibitor Ganetespib, in Dogs with Spontaneous Cancer
por: London, Cheryl A., et al.
Publicado: (2011)

The MRL/lpr Mouse Strain as a Model for Neuropsychiatric Systemic Lupus Erythematosus
por: Gulinello, Maria, et al.
Publicado: (2011)

Influence of thymic genotype on the systemic lupus erythematosus-like disease and T cell proliferation of MRL/Mp-lpr/lpr mice
Publicado: (1981)

The HSP90 inhibitor ganetespib has chemosensitizer and radiosensitizer activity in colorectal cancer
por: He, Suqin, et al.
Publicado: (2014)

Neuropsychiatric systemic lupus erythematosus persists despite attenuation of systemic disease in MRL/lpr mice
por: Stock, Ariel D., et al.
Publicado: (2015)

Chlorogenic Acid Relieves the Lupus Erythematosus-like Skin Lesions and Arthritis in MRL/lpr Mice
por: Wang, Ruxuan, et al.
Publicado: (2022)

Prolactin Levels Correlate with Abnormal B Cell Maturation in MRL and MRL/lpr Mouse Models of Systemic Lupus Erythematosus-Like Disease
por: Legorreta-Haquet, Maria Victoria, et al.
Publicado: (2013)

The HSP90 Inhibitor Ganetespib Radiosensitizes Human Lung Adenocarcinoma Cells
por: Gomez-Casal, Roberto, et al.
Publicado: (2015)

Efficacy of an HSP90 inhibitor, ganetespib, in preclinical thyroid cancer models
por: Lin, Shu-Fu, et al.
Publicado: (2017)

Self-Reactivity and the Expression of Memory Markers Vary Independently in MRL-Mp+/+ and MRL-Mp-lpr/lpr Mice
por: Smyth, Lesley, et al.
Publicado: (1992)

Naja naja atra Venom Protects against Manifestations of Systemic Lupus Erythematosus in MRL/lpr Mice
por: Zhu, Jiali, et al.
Publicado: (2014)

Anti-RNA polymerase I antibodies in sera of MRL lpr/lpr and MRL +/+ autoimmune mice. Correlation of antibody production with delayed onset of lupus-like disease in MRL +/+ mice
Publicado: (1985)

Nitric oxide as an inflammatory mediator in autoimmune MRL-lpr/lpr mice.
por: Weinberg, J B
Publicado: (1998)

Reduced receptor editing in lupus-prone MRL/lpr mice
por: Lamoureux, Jennifer L., et al.
Publicado: (2007)

ALW peptide ameliorates lupus nephritis in MRL/lpr mice
por: Wang, Huixia, et al.
Publicado: (2019)

HSP-90 Inhibitor Ganetespib is Synergistic with Doxorubicin in Small Cell Lung Cancer
por: Lai, Chien-Hao, et al.
Publicado: (2013)

Effects of Hsp90 Inhibitor Ganetespib on Inhibition of Azole-Resistant Candida albicans
por: Yuan, Rui, et al.
Publicado: (2021)

Immunomodulatory effects of atorvastatin on MRL/lpr mice
por: Sun, Jing, et al.
Publicado: (2022)

Defective maintenance of T cell tolerance to a superantigen in MRL- lpr/lpr mice
Publicado: (1992)

The HSP90 Inhibitor, 17-AAG, Influences the Activation and Proliferation of T Lymphocytes via AKT/GSK3β Signaling in MRL/lpr Mice
por: Hong, Liang-Jian, et al.
Publicado: (2020)

Murine lupus is neutrophil elastase-independent in the MRL.Fas(lpr) model
por: Gordon, Rachael A., et al.
Publicado: (2020)

Intermittent Fasting Aggravates Lupus Nephritis through Increasing Survival and Autophagy of Antibody Secreting Cells in MRL/lpr Mice
por: Hong, Seung-Min, et al.
Publicado: (2020)

Corrigendum: Effects of Hsp90 Inhibitor Ganetespib on Inhibition of Azole-Resistant Candida albicans
por: Yuan, Rui, et al.
Publicado: (2021)

The Protective Effects of Ultraviolet A1 Irradiation on Spontaneous Lupus Erythematosus-Like Skin Lesions in MRL/lpr Mice
por: Mikita, Naoya, et al.
Publicado: (2009)

Targeting the Protective Arm of the Renin-Angiotensin System to Reduce Systemic Lupus Erythematosus Related Pathologies in MRL-lpr Mice
por: Soto, Maira, et al.
Publicado: (2020)

An Impermeant Ganetespib Analog Inhibits Extracellular Hsp90-Mediated Cancer Cell Migration that Involves Lysyl Oxidase 2-like Protein
por: McCready, Jessica, et al.
Publicado: (2014)

Multifaceted Intervention by the Hsp90 Inhibitor Ganetespib (STA-9090) in Cancer Cells with Activated JAK/STAT Signaling
por: Proia, David A., et al.
Publicado: (2011)

Reduction of lupus nephritis in MRL/lpr mice by a bacterial superantigen treatment
Publicado: (1991)

Fecal microbiota from MRL/lpr mice exacerbates pristane-induced lupus
por: Yi, Xiaoqing, et al.
Publicado: (2023)

Role of Ganetespib, an HSP90 Inhibitor, in Cancer Therapy: From Molecular Mechanisms to Clinical Practice
por: Youssef, Mahmoud E., et al.
Publicado: (2023)

Drug-like analogues of the parasitic worm-derived immunomodulator ES-62 are therapeutic in the MRL/Lpr model of systemic lupus erythematosus
por: Rodgers, D T, et al.
Publicado: (2015)

The contribution of L3T4+ T cells to lymphoproliferation and autoantibody production in MRL-lpr/lpr mice
Publicado: (1988)

Complement Properdin Determines Disease Activity in MRL/lpr Mice
por: Alaridhee, Hasanain, et al.
Publicado: (2020)

Monoclonal IgM rheumatoid factors derived from arthritic MRL/Mp-lpr/lpr mice
Publicado: (1983)

Anti-inflammatory activities of Ganoderma lucidum (Lingzhi) and San-Miao-San supplements in MRL/lpr mice for the treatment of systemic lupus erythematosus
por: Cai, Zhe, et al.
Publicado: (2016)

Targeted inhibition of Hsp90 by ganetespib is effective across a broad spectrum of breast cancer subtypes
por: Friedland, Julie C., et al.
Publicado: (2013)

Synergistic activity of the Hsp90 inhibitor ganetespib with taxanes in non-small cell lung cancer models
por: Proia, David A., et al.
Publicado: (2012)

The HSP90 inhibitor ganetespib: A potential effective agent for Acute Myeloid Leukemia in combination with cytarabine
por: Lazenby, M., et al.
Publicado: (2015)

Safety and efficacy of HSP90 inhibitor ganetespib for neoadjuvant treatment of stage II/III breast cancer
por: Lang, Julie E., et al.
Publicado: (2022)

The new complement inhibitor CRIg/FH ameliorates lupus nephritis in lupus-prone MRL/lpr mice
por: Shi, Yu, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_mbp4n95orce4qpjpk309hp4dn6